Acalabrutinib (Calquence) coverage
Customize your policy alerts
Sign up for mhn Policy CP.PHAR.366 alerts
Get alerted when Policy CP.PHAR.366 changes without checking for updates manually.
Monitor payer policy activity
Medical necessity and prior authorization criteria for acalabrutinib (Calquence) for adult patients with mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and selected off-label B-cell malignancies; applies to providers and members covered under the payer's Commercial, HIM and Medicaid lines of business.
Added NCCN-supported use: first-line therapy for CLL/SLL in combination with venetoclax (Venclexta).
Updated initial authorization durations from 6 months to 12 months for Medicaid/HIM.
Updated conditions for first-line use in CLL/SLL to align with recent FDA approval adding AMPLIFY trial results to the Calquence PI.
Added tablet formulation dosing/regimen language and tablet product availability.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.